Chase Investment Counsel Corp acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 4,000 shares of the biotechnology company’s stock, valued at approximately $2,167,000.
A number of other large investors have also recently made changes to their positions in UTHR. Geneos Wealth Management Inc. increased its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 70 shares in the last quarter. Jump Financial LLC bought a new stake in United Therapeutics in the second quarter valued at $277,000. Cerity Partners LLC increased its position in United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia increased its position in United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the period. 94.08% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $565.98, for a total transaction of $5,376,810.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,929,547.74. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,648,140.36. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 443,075 shares of company stock valued at $241,508,744 in the last quarter. 8.60% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on UTHR
United Therapeutics Stock Performance
UTHR stock opened at $499.73 on Monday. The firm has a 50 day moving average price of $535.95 and a 200-day moving average price of $536.15. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The firm has a market capitalization of $21.43 billion, a price-to-earnings ratio of 17.88, a PEG ratio of 1.69 and a beta of 0.59.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.41 EPS. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
- Five stocks we like better than United Therapeutics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
